Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial

Abstract EN

Background.

Anorexia occurs in about half of cancer patients and is associated with high mortality rate.

However, safe and long-term use of anorexia treatment is still an unmet need.

Objective.

The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia.

Methods.

A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group.

Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks.

The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT).

The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests.

Results.

Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment.

However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group.

Conclusions.

Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer.

Further large-scale studies are needed to ensure the efficacy.

Trial Registration.

This trial is registered with ClinicalTrials.gov NCT02468141.